Key terms
About BRTX
BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. Its programs provide quality of care for chronic back pain caused by disc degeneration and metabolic disorders, including obesity and diabetes. The company's initial investigational therapeutic product being called BRTX-100 focuses on treating damage by an autologous stem cell product that uses own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. BioRestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BRTX news
Apr 17
4:05pm ET
Optimistic Outlook for BioRestorative Therapies Backed by Clinical and Strategic Advances
Apr 16
11:31am ET
BioRestorative’s BRTX-100 trial to use sham injection control, says Roth MKM
Apr 16
7:50am ET
BioRestorative announces FDA clearance of Phase 2 BRTX-100 study protocol
Apr 08
7:47am ET
BioRestorative partners with Galen Patient Recruitment for BRTX-100 trial
Apr 03
4:39pm ET
BioRestorative Therapies files registration statement of Form S-1
Apr 03
4:20pm ET
BioRestorative Therapies files to sell 2.51M shares of common stock for holders
Mar 12
7:42am ET
BioRestorative Therapies Clarifies Disclosure Regulations Impact
Feb 09
4:38am ET
BioRestorative Therapies Sparks Investor Interest with New Transaction
Feb 09
4:38am ET
BioRestorative Therapies Secures $8.1M Through Warrant Restructuring
Feb 06
2:46pm ET
Promising Early Phase 2 Results for BioRestorative Therapies’ BRTX-100 Lead to Buy Rating
Feb 06
8:27am ET
BioRestorative announces exercise of warrants, issuance of new warrants
Feb 06
4:18am ET
BioRestorative Therapies Clarifies Disclosure Liability Limits
Feb 05
7:32am ET
BioRestorative presents preliminary data from Phase 2 study of BRTX-100
Feb 01
7:32am ET
BioRestorative Therapies to present preliminary BRTX-100 data at ORS meeting
BRTX Financials
Key terms
Ad Feedback
BRTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BRTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range